K7 LUMBAR SPACERS

K133126 · K7, LLC · MAX · Dec 9, 2013 · Orthopedic

Device Facts

Record IDK133126
Device NameK7 LUMBAR SPACERS
ApplicantK7, LLC
Product CodeMAX · Orthopedic
Decision DateDec 9, 2013
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3080
Device ClassClass 2
AttributesTherapeutic

Intended Use

The K7 Lumbar Spacers are indicated for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device is intended for use with supplemental fixation and with autograft to facilitate fusion

Device Story

K7 Lumbar Spacers are radiolucent interbody fusion devices; hollow column design with parallel serrations on superior/inferior surfaces for stability. Available in various heights, lengths, widths, and angulations to accommodate patient anatomy. Used by surgeons in clinical settings for lumbar spine fusion. Device acts as a structural spacer to maintain disc space height while facilitating fusion when used with autograft and supplemental fixation. Benefits include stabilization of spinal segments in patients with degenerative disc disease.

Clinical Evidence

Bench testing only. Mechanical testing performed per ASTM F2077 (static and dynamic compression) and ASTM F2267 (subsidence). No clinical data provided.

Technological Characteristics

Materials: PEEK (ASTM F2026) and tantalum marker pins (ASTM F560). Design: Radiolucent hollow column with serrated surfaces. Dimensions: Variable heights, lengths, widths, and angulations. Sterilization: Not specified.

Indications for Use

Indicated for intervertebral body fusion of lumbar spine (L2-S1) in skeletally mature patients with 6 months of failed non-operative treatment. Used for degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis. Requires supplemental fixation and autograft.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ : . | 510(k) Summary | | | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------| | Date: | 26 September 2013 | DEC - 9 2013 | | Sponsor: | K7 LLC<br>54 Moonrise Way<br>Henderson, NV 89074<br>Phone: 817.219.4441<br>Facsimile: 817.326.5524 | | | Contact Person: | Michael D. Smith, Manager | | | Trade Names: | K7 Lumbar Spacers | | | Device Classification | Class II | | | Classification Name: | Intervertebral fusion device with bone graft, lumbar | | | Regulation: | 888.3080 | | | Device Product<br>Code: | MAX | | | Device Description: | The K7 Lumbar Spacers are a collection of radiolucent interbody<br>devices having variously shaped cross-sections. The superior and<br>inferior surfaces are open with parallel serrations to facilitate implant<br>stability. The implants are available in an assortment of height,<br>length, width and anteroposterior angulation combinations to<br>accommodate a variety of anatomic requirements. | | | Intended Use: | The K7 Lumbar Spacers are indicated for intervertebral body fusion<br>of the lumbar spine, from L2 to S1, in skeletally mature patients who<br>have had six months of non-operative treatment. The device is<br>intended for use at either one level or two contiguous levels for the<br>treatment of degenerative disc disease (DDD) with up to Grade I<br>spondylolisthesis or retrolisthesis. DDD is defined as back pain of<br>discogenic origin with degeneration of the disc confirmed by history<br>and radiographic studies. The device is intended for use with<br>supplemental fixation and with autograft to facilitate fusion | | | Materials: | K7 Lumbar Spacers are manufactured from polyetheretherketone<br>(PEEK) per ASTM F2026 (VESTAKEEP® i4 R, Evonik Polymers<br>Technologies GmbH). Integral marker pins are manufactured from<br>tantalum according to ASTM F560. | | | Predicate Devices: | Eminent Spine, Eminent Spine Interbody Fusion System (K090064)<br>DePuy AcroMed, Lumbar I/F Cage® (P960025)<br>DePuy Spine, Cougar LS Lateral Cage System (K090899, K110454)<br>Choice Spine LP, ORIA Natura® (K073669)<br>K2M, Aleutian® IBF System (K082698, K101302 and K110843)<br>Stryker Spine, AVS® PEEK Spacers (K073470, K082014, K101051)<br>Icotec, ETurn Spinal Implant (K100305) | | . . . . . . . . : : {1}------------------------------------------------ Performance Data: Mechanical testing of the worst case K7 Lumbar Spacer was performed according to ASTM F2077 and included static and dynamic compression. The subsidence properties were evaluated according to ASTM F2267. The mechanical test results demonstrate that the K7 Lumbar Spacers performance is substantially equivalent to the predicate devices. Technological The K7 Lumbar Spacers possess the same technological Characteristics: characteristics as the predicate devices. These include: intended use (as described above), . . basic design (hollow column), material (PEEK polymer and tantalum), and . sizes (widths, lengths and heights are within the range(s) . offered by the predicate systems). Therefore the fundamental scientific technology of the K7 Lumbar Spacers is the same as previously cleared devices. The K7 Lumbar Spacers possess the same intended use and technological characteristics as the predicate devices. Therefore the K7 Lumbar Spacer system is substantially equivalent for its intended use. ## Conclusion: Page 119 {2}------------------------------------------------ Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 December 9. 2013 K7. LLC % BackRoads Consulting, Incorporated Karen E. Warden. Ph.D. 8202 Sherman Road Chesterland, Ohio 44026 Re: K133126 Trade/Device Name: K7 Lumbar Spacers Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: September 26, 2013 Received: September 30, 2013 Dear Dr. Warden: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set {3}------------------------------------------------ ## Page 2 - Karen E. Warden, Ph.D. forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda,gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, ## Ronalde Jean -S for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Section 7 - Indications for Use Statement 510(k) Number:_K133126 Device Name: K7 Lumbar Spacers Indications for Use: The K7 Lumbar Spacers are indicated for intervertebral body fusion of the lumbar spine, from L2 to S1. in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device is intended for use with supplemental fixation and with autograft to facilitate fusion. > Prescription Use X OR Over-the-Counter Use_ ________________________________________________________________________________________________________________________________________________________ > > (Per 21 CFR 801.109) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Anton E. Dmitriev, PhD Division of Orthopedic Devices
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...